表达IL-15的CD70特异性CAR NK细胞用于治疗CD19阴性B细胞恶性肿瘤
研究构建了含4-1BB共刺激域和白介素-15(IL-15)的CD70特异性第四代CAR,经狒狒包膜假型慢病毒载体转导至脐带血来源NK细胞。CD70-CAR NK细胞在体外和体内对CD19阴性B细胞淋巴瘤的细胞毒活性优于未转导NK细胞和CD19特异性CAR NK细胞。小鼠接受2剂CD70-CAR NK细胞后肿瘤有效清除,血浆IL-15浓度升高,CAR NK细胞增殖和持久性增强。
要点
- CD70-CAR NK细胞体外和体内对CD19阴性B细胞淋巴瘤细胞毒活性优于未转导NK细胞和CD19-CAR NK细胞。
- 小鼠接受2剂CD70-CAR NK细胞后肿瘤有效清除,伴血浆IL-15浓度升高和CAR NK细胞增殖、持久性增强。
- 研究提示重复给药CAR NK细胞疗法相比单剂CAR NK细胞对B细胞淋巴瘤治疗具有临床优势。
核心结论
- 研究提示基于重复给药的CAR NK细胞疗法相比单剂CAR NK细胞治疗B细胞淋巴瘤具有临床优势。
研究设计与样本
- 研究将含4-1BB共刺激域和IL-15的CD70特异性第四代CAR通过狒狒包膜假型慢病毒载体转导至脐带血来源NK细胞,并在体外和小鼠体内进行功能评价。
主要发现
- CD70-CAR NK细胞体外和体内对CD19阴性B细胞淋巴瘤的细胞毒活性优于未转导NK细胞和CD19特异性CAR NK细胞。
- 小鼠接受2剂CD70-CAR NK细胞后肿瘤有效清除,伴血浆IL-15浓度升高及CAR NK细胞增殖和持久性增强。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) natural killer (NK) cells can eliminate tumors not only through the ability of the CAR molecule to recognize antigen-expressed cancer cells but also through NK-cell receptors themselves. This overcomes some of the limitations of CAR T cells, paving the way for CAR NK cells for safer and more effective off-the-shelf cellular therapy. In this study, CD70-specific (a pan-target of lymphoma) fourth-generation CAR with 4-1BB costimulatory domain and interleukin-15 (IL-15) was constructed and transduced into cord blood-derived NK cells by Baboon envelope pseudotyped lentiviral vector. CD70-CAR NK cells displayed superior cytotoxic activity in vitro and in vivo against CD19-negative B-cell lymphoma when compared with nontransduced NK cells and CD19-specific CAR NK cells. Importantly, mice that received 2 doses of CD70-CAR NK cells showed effective eradication of tumors, accompanied by increased concentration of plasma IL-15 and enhanced CAR NK cell proliferation and persistence. Our study suggests that repetitive administration-based CAR NK-cell therapy has clinical advantage compared with a single dose of CAR NK cells for the treatment of B-cell lymphoma.
引用
- Guo S, Lei W, Jin X, et al. CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy. Blood Adv. 2024. PMID: 38564778. doi:10.1182/bloodadvances.2023012202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。